Investment Rating - The report indicates a positive outlook for the pharmaceutical sector, particularly for innovative drugs and companies expected to reach profitability in 2025 [1][9][15]. Core Insights - The innovative drug sector is anticipated to see significant growth due to the commercialization of core products and contributions from business development (BD) revenues, with companies like BeiGene, Innovent Biologics, and others expected to achieve profitability [1][9]. - The Pharma sub-sector is projected to experience a revenue growth rate of 15-20% in 2025, with notable companies such as Hansoh Pharmaceutical and China Biologic Products leading this growth [2][10]. - The CXO sector is also expected to report strong performance, with companies like WuXi AppTec forecasting substantial revenue and profit increases [3][11]. - The medical services sector is currently valued at historical lows, with a projected revenue growth of 13% for Genscript Biotech, highlighting the importance of monitoring industry changes [4][12]. Summary by Sections Innovative Drugs - Companies expected to achieve profitability in 2025 include BeiGene, Innovent Biologics, and others, driven by increased commercialization and BD revenues [1][9]. Pharma - Revenue growth of 15-20% is expected for leading companies such as Hansoh Pharmaceutical and China Biologic Products, with a significant boost anticipated for 3SBio due to a major BD deal with Pfizer [2][10]. CXO - WuXi AppTec is projected to achieve approximately 454.56 billion RMB in revenue, reflecting a year-on-year growth of about 15.84%, with adjusted net profits expected to rise significantly [3][11]. Medical Services - Genscript Biotech is expected to see a revenue increase of 13% in 2025, emphasizing the need to focus on overseas business expansion and AI integration in traditional medicine [4][12].

Investment Rating - The report recommends an "Overweight" rating for new consumption, solid-state batteries, and innovative drugs, indicating a potential increase in value exceeding the market benchmark by more than 10% over the next 6-12 months [5][21]. Core Insights - The report highlights that adjustments in the market present good buying opportunities, particularly in the sectors of new consumption, solid-state batteries, and innovative drugs, with a focus on recent catalysts in AI applications [5]. - The overall trend in emerging industries is characterized by a strong fundamental outlook but a weak technical position, suggesting potential for growth despite current market pressures [16][17]. Summary by Relevant Categories New Consumption - The sector is rated "Overweight" with a strong technical outlook, indicating a low position that is expected to recover [5]. - Recent government initiatives, such as the "2026 'Happy Shopping Spring' Special Activity Plan," are expected to support growth in this sector [5]. Solid-State Batteries - Rated "Overweight," this sector shows a strong technical outlook with expectations for a low position to rebound [5]. - Companies like Xinwangda are advancing in the production of semi-solid-state batteries, with mass production anticipated by 2027 [5]. Innovative Drugs - The sector is also rated "Overweight," with a strong technical outlook and a low position that is still in the recovery phase [5]. - Recent developments include the completion of Phase III clinical trials for innovative drugs, indicating progress in the sector [5]. AI Applications and Computing Infrastructure - The report notes a neutral rating for AI applications and computing infrastructure, with moderate growth expectations and recent advancements in national supercomputing capabilities [5][10]. - The launch of the national supercomputing internet core node is expected to provide significant AI computing resources [10]. Commercial Aerospace - Rated as "Neutral," the commercial aerospace sector is experiencing high levels of activity but is under adjustment pressure [5]. - Recent developments include SpaceX's application to launch a large number of satellites, which could redefine AI resource competition [10]. Humanoid Robots - The sector is rated "Neutral+" with a strong technical outlook, as Tesla announces plans for mass production of its humanoid robot by 2026 [5][10]. Gaming - The gaming sector is rated "Neutral+" with a strong technical outlook, but recent developments have led to a downward adjustment in expectations [5][10]. - The release of Google's Genie 3 has caused volatility in the market, but it is viewed as a tool for development rather than a disruptive technology [10].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant growth in License-out transactions from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in early 2026, with the pharmaceutical and biological sector rising by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In early 2026, significant deals were made, including a $12 billion upfront payment from CSPC to AstraZeneca, indicating the growing international competitiveness of Chinese innovative drugs [16][17] Section 2: Performance of the Pharmaceutical Sector - The pharmaceutical sector has shown robust growth, with companies like BeiGene reporting revenues exceeding 36 billion yuan, reflecting strong commercialization capabilities [6][23] - The overall industry is moving towards profitability, with companies like Innovent Biologics and Rongchang Biopharma achieving breakeven for the first time [6][23] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the Chinese pharmaceutical sector saw a 0.14% increase, with traditional Chinese medicine leading the gains at 2.56% [7][31] - The medical research outsourcing sector also performed well, increasing by 1.99%, while other subsectors like biological products and vaccines experienced declines [7][31][35]

- The report highlights the monthly performance of strong stocks, indicating that despite the adjustment of heavyweight stocks, small-cap stocks provided a hedge, but the overall market profitability was weak, with total market turnover dropping from 3.99 trillion yuan on January 14 to 2.16 trillion yuan on February 6[6] - The top 20 stocks with the highest gains in February are listed, including sectors such as space photovoltaics, batteries, copper connections, innovative drugs, real estate, and more, with the highest gain reaching 80.52% for *ST立方[6] - The report provides a detailed analysis of the maximum gains in various sectors since the start of the bull market, with telecommunications and metal materials/mining sectors achieving the highest gains of 218% and 217%, respectively, from February 5, 2024, to February 7, 2026[9]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The Chinese innovative pharmaceutical industry is entering a new phase of development characterized by dual breakthroughs in commercialization and internationalization, with significant increases in License-out transaction values from $2.562 billion in 2017 to $140.274 billion in 2025 [5][15] - The industry is transitioning from a phase of pipeline expectations to one of performance realization, with over 70% of companies achieving positive revenue growth in 2025 [6][23] - The innovative drug sector has seen a strong performance in the first week of February 2026, with a 0.14% increase, outperforming the CSI 300 index by 1.47 percentage points [7][29] Summary by Sections Section 1: Breakthroughs in Commercialization and Internationalization - The period from 2017 to 2026 is crucial for the recognition of Chinese pharmaceutical companies in the global market, with a notable increase in License-out transactions [5][15] - In 2026, the upfront payment for License-out transactions has already exceeded 39% of the total for 2025, indicating improved quality and competitiveness of Chinese innovative drug pipelines [5][15][16] Section 2: Performance of the Pharmaceutical Sector - The innovative drug sector is experiencing rapid revenue growth, with companies like BeiGene achieving over 36 billion yuan in revenue, showcasing strong commercialization capabilities [6][23] - Major companies such as Innovent Biologics and Rongchang Biopharma have maintained robust growth due to their core products, with some companies achieving profitability for the first time [6][23][24] Section 3: Market Trends and Subsector Performance - In the first week of February 2026, the traditional Chinese medicine sector saw the highest increase at 2.56%, while other biopharmaceutical sectors experienced declines [7][31] - The medical research outsourcing sector also performed well, with a 1.99% increase, indicating a positive trend in the pharmaceutical industry overall [7][31][35]

由此来看，近期海外一系列不确定性因素对风险资产的冲击更多是在叙事与情绪层面，而并非基本面或 政策路径出现实质性变化，尤其是支撑春季行情的国内核心逻辑——向好的基本面、政策"开门红" 与 充裕的流动性均未发生任何改变，这也是我们看好春季行情尚未结束的核心原因。 往后看，随着前期调整释放一定风险，近期全球叙事变化对市场情绪冲击最大的时刻或正在逐步过去。 一方面，从资产表现来看，周五（2月6日）比特币、美股、中概股、贵金属等一系列风险资产企稳反 弹，表明全球风险偏好已在逐步修复；另一方面，从我们跟踪的一系列情绪指标来看，当前A股与港股 已调整出一定的性价比，尤其是我们构建的港股情绪指数已经回落至去年12月19日底部的水平，并跌穿 滚动一年均值-1.5倍标准差，显示港股已到值得重点关注的区间。 从事件催化和日历效应的角度来看，后续也将逐步进入一个有利于权益资产演绎的良好环境。事件催化 角度，下周即将进入中美宏观数据的披露窗口，国内物价、社融等数据对于基本面改善的验证值得期 待，美国非农和CPI数据也有望对货币政策预期形成校准。此外，国内外AI应用等产业层面的密集催化 也有望在春节前后集中演绎。经历近期轮动加快、主线降 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it will outperform the overall market [1]. Core Insights - The report highlights that the commercialization of innovative drugs, combined with licensing income, is expected to lead to profitability for several companies in 2025, including BeiGene, Innovent Biologics, and others [1][9]. - The Pharma sub-sector is projected to achieve a revenue growth rate of 15-20% in 2025 for companies like Hansoh Pharmaceutical and China Biologic Products, with a significant revenue increase expected for 3SBio due to a major business development deal with Pfizer [2][10]. - The CXO sector is also expected to show strong performance, with companies like WuXi AppTec forecasting a revenue increase of approximately 15.84% and a net profit growth of about 102.65% in 2025 [3][11]. - In the medical services sector, the report notes that valuations are at historical lows, with a projected revenue growth of 13% for GuoShengTang in 2025, emphasizing the importance of overseas business expansion and AI integration in traditional Chinese medicine [4][12]. Summary by Sections Innovative Drugs - The report anticipates that several innovative drug companies will reach profitability in 2025 due to increased commercialization and business development income [9][15]. Pharma - The Pharma sub-sector is expected to see a revenue growth of 15-20% in 2025 for key players, with 3SBio projected to achieve over 100% growth due to a significant partnership with Pfizer [2][10]. CXO - WuXi AppTec is expected to report a revenue of approximately 454.56 billion RMB in 2025, with a net profit growth of around 102.65% [3][11]. Medical Services - GuoShengTang is projected to have a revenue growth of 13% in 2025, with a focus on overseas acquisitions and AI applications in traditional medicine [4][12].

Group 1 - The recent global risk asset adjustment is primarily driven by narrative and sentiment rather than fundamental or policy changes, indicating a rebalancing of global assets and internal styles [10][25][32] - The core logic supporting the spring market remains unchanged, with positive fundamentals, favorable policies, and ample liquidity still in place [3][25][28] - The upcoming macro data releases from China and the US are expected to validate improvements in fundamentals, which could enhance market sentiment [7][28] Group 2 - The post-Spring Festival market is anticipated to favor technology manufacturing, resource products, and infrastructure chains, driven by an increase in risk appetite [11][32] - Key sectors to focus on include TMT (Technology, Media, and Telecommunications), high-end manufacturing (such as renewable energy and innovative pharmaceuticals), and price recovery chains (including chemicals, building materials, and steel) [14][35][38] - The AI application sector is expected to see concentrated catalysts, with its current crowding level being reasonable, making it a focal point for investment [17][38]

Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The top-level policy for traditional Chinese medicine (TCM) has been clarified, emphasizing high-quality development and supporting industry leaders. The "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" was released on February 6, 2026, outlining the development framework for the next five years. The plan highlights the importance of leading companies and innovation in driving industry growth [5][16][21]. - The TCM sector is expected to experience a turning point due to policy support, improved consumer environment, declining raw material prices, and inventory clearance. Key companies to watch include brand TCM firms like China Resources Sanjiu, Dong-E E-Jiao, Jiangzhong Pharmaceutical, and Mayinglong, as well as innovative TCM drug companies like Yiling Pharmaceutical and Fangsheng Pharmaceutical [5][22]. Market Review - In the week from February 2 to February 6, 2026, the CITIC Pharmaceutical Index rose by 0.3%, outperforming the CSI 300 Index by 1.7 percentage points, ranking 12th among CITIC's primary industry classifications. Since the beginning of 2026, the CITIC Pharmaceutical and Biotech sector index has increased by 3.3%, also outperforming the CSI 300 Index by 3.0 percentage points, ranking 19th [4][25]. - The top five performing stocks during this week were: Guangshentang (+29.8%), Haixiang Pharmaceutical (+18.6%), Meidixi (+18.0%), Tianzhihang (+17.6%), and Saike Xide (+14.5%) [4][39]. Short-term Investment Thoughts - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with market sentiment expected to reverse around the Spring Festival. The performance of traditional Chinese medicine has been particularly strong, likely due to the recent policy announcements. The report suggests focusing on innovative drugs, medical devices, and companies benefiting from domestic demand [6][22]. - Recommended stocks for February include Heng Rui Medicine, Kangfang Biotech, Baiji Shenzhou, Ying'en Biotech, Tiger Medical, Microelectrophysiology, Huana Pharmaceutical, and Haite Biotech [6][12].

Investment Rating - The industry investment rating is "Positive" and maintained [10] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by the influx of funds from A/H listings and capital increases of innovative drug companies, leading to an improvement in the willingness to invest in R&D [2][41] - The trend of IPOs for innovative drug companies is on the rise, with significant fundraising observed, indicating a widening of the listing channels for innovative drugs [6][29] - The overall financing amount in China's biopharmaceutical sector is showing signs of recovery, with a notable year-on-year increase in investment amounts [8][35] Summary by Sections Innovative Drug R&D Investment Trends - The willingness to invest in R&D for innovative drugs is improving, supported by increased cash flow and favorable financing conditions for both Pharma and Biotech companies [22] - The trend indicators for innovative drug R&D investment are showing positive signs, suggesting a potential upturn in the industry [22] IPO and Fundraising Trends - The IPO fundraising for innovative drug companies in Hong Kong has significantly improved, with a total of 30 billion yuan raised in January 2026, marking a 287% year-on-year increase [29] - The A-share market is also seeing a positive trend in IPO fundraising, with expectations for gradual improvement as the listing channels for unprofitable companies continue to expand [6][29] Financing and Investment Recovery - The total financing amount in China's biopharmaceutical sector reached 1.2 billion USD in January 2026, reflecting a 106% year-on-year increase, indicating a potential recovery from previous lows [8][35] - The trend of external BD upfront payments has become a significant source of funding for R&D, with January 2026 seeing a record high of 2.26 billion USD in upfront payments [9][38]